Evusheld COVID-19 therapy approved in EU
Evusheld becomes first and only long-acting antibody combination available for both prevention and treatment of COVID-19 in Europe.
List view / Grid view
Evusheld becomes first and only long-acting antibody combination available for both prevention and treatment of COVID-19 in Europe.
All twenty long-COVID patients who received neuromodulation treatment reported significant improvements in their symptoms in just 14 days.